By SPC News Staff
The FDA approved spesolimab-sbzo (Spevigo, Boehringer Ingelheim) for generalized pustular psoriasis (GPP) flares in adults. More than half of patients treated with the drug, which is the first to receive approval for GPP flares, had no visible pustules after one week.
Spesolimab is a monoclonal antibody that blocks interleukin-36 signaling within the immune system. The drug’s approval is based on results from the 12-week, placebo-controlled Effisayil 1 phase 2 clinical